Scholars Central

EditorialPublished 27 Aug 2020

Clinical News

Authors: Peter F. Buckley

Clinical Schizophrenia & Related Psychoses

Volume 10 · Issue 3 · Pages 85–88

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Our field can be encouraged by several developments in the psychopharmacology of schizophrenia. We have previously described the initial clinical trials program of ITI-007. Results of two Phase 3 trials of ITI-007 have been reported as positive, with demonstrated antipsychotic efficacy and a favorable side effect profile (most prominently, mild sedation).

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical Schizophrenia & Related Psychoses.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Schizophrenia & Related Psychoses
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “Peter F. Buckley”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels